GLP-1 stands for glucagon-like peptide-1, a hormone released in your gut after you eat
However: Larger meta-analyses show no significant increase in risk after adjusting for confounders [25] Incidence appears similar to other diabetes therapies [25] Much of the observed signal likely reflects: Baseline risk (obesity, T2DM) Secondary gallstone disease In summary, pancreatitis in GLP-1 users is a rare and possible complication, but current evidence does not support a substantial increase in risk directly related to GLP-1 agents
This long duration is a key advantage that sets Vyvanse apart from other stimulants, such as Adderall XR or Focalin XR
They often come with a heavy tax: brain fog, fatigue, and the dreaded "rebound cycle" (Medication Overuse Headache)
Mehdizadeh, M., Aguilar, M., Thorin, E., Ferbeyre, G